ARTICLE | Company News
Amgen, Isis deal
January 7, 2002 8:00 AM UTC
AMGN expanded its antisense deal with ISIP to include access to certain GeneTrove division IP and patents, including in-house use of ISIP's ribonuclease H (RNase H) mechanism of action technology. The...